MX370647B - Formulación farmacéutica que tiene estabilidad mejorada. - Google Patents
Formulación farmacéutica que tiene estabilidad mejorada.Info
- Publication number
- MX370647B MX370647B MX2014009871A MX2014009871A MX370647B MX 370647 B MX370647 B MX 370647B MX 2014009871 A MX2014009871 A MX 2014009871A MX 2014009871 A MX2014009871 A MX 2014009871A MX 370647 B MX370647 B MX 370647B
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutical formulation
- improved stability
- ramipril
- desintegrant
- binder
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 abstract 2
- 229960003401 ramipril Drugs 0.000 abstract 2
- 239000011230 binding agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a una formulación farmacéutica que contiene ramipril con estabilidad mejorada, que comprende ramipril y un disgregante directamente granulado con un aglutinante.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/HU2012/000013 WO2013121233A1 (en) | 2012-02-17 | 2012-02-17 | Pharmaceutical formulation having improved stability |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2014009871A MX2014009871A (es) | 2015-03-19 |
MX370647B true MX370647B (es) | 2019-12-19 |
Family
ID=45922707
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014009871A MX370647B (es) | 2012-02-17 | 2012-02-17 | Formulación farmacéutica que tiene estabilidad mejorada. |
Country Status (16)
Country | Link |
---|---|
US (1) | US20150094345A1 (es) |
EP (2) | EP2814465B1 (es) |
CN (2) | CN104254321A (es) |
AU (2) | AU2012369903A1 (es) |
BR (1) | BR112014020184B1 (es) |
CA (1) | CA2864456A1 (es) |
EA (1) | EA030466B1 (es) |
HK (1) | HK1205683A1 (es) |
HU (1) | HUE046229T2 (es) |
IL (1) | IL233972A0 (es) |
MX (1) | MX370647B (es) |
PH (1) | PH12014501840A1 (es) |
PL (1) | PL2814465T3 (es) |
UA (1) | UA113977C2 (es) |
WO (1) | WO2013121233A1 (es) |
ZA (1) | ZA201405925B (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012011118A2 (en) * | 2010-05-13 | 2012-01-26 | Purshotama Sagi Reddy Babu Reddy | Development of a fixed dose combination dosage form containing ramipril and carvedilol |
US20150094345A1 (en) | 2012-02-17 | 2015-04-02 | Egis Gyogyszergyar Zrt. | Pharmaceutical formulation having improved stability |
HUP1300496A2 (hu) | 2013-08-16 | 2015-03-02 | Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag | Stabil kombinációs gyógyszerkészítmény |
EP3886817A1 (en) | 2018-11-27 | 2021-10-06 | Zaklady Farmaceutyczne Polpharma S.A. | Pharmaceutical composition comprising ramipril and indapamide |
CN114748436B (zh) * | 2022-05-30 | 2023-05-16 | 迪沙药业集团有限公司 | 一种硝苯地平组合物及其制备方法 |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3174844D1 (en) | 1980-10-23 | 1986-07-24 | Schering Corp | Carboxyalkyl dipeptides, processes for their production and pharmaceutical compositions containing them |
DE3226768A1 (de) | 1981-11-05 | 1983-05-26 | Hoechst Ag, 6230 Frankfurt | Derivate der cis, endo-2-azabicyclo-(3.3.0)-octan-3-carbonsaeure, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung |
DE3739690A1 (de) | 1987-11-24 | 1989-06-08 | Hoechst Ag | Stabilisierte arzneistoffe, verfahren zu ihrer herstellung sowie stabile arzneizubereitungen |
FR2824477B1 (fr) * | 2001-05-09 | 2005-09-09 | Ethypharm Lab Prod Ethiques | Granules enrobes a base d'inhibiteur de l'enzyme de conversion de l'anfiotensine, leur procede de preparation et comprimes orodispersibles contenant les granules enrobes |
HU226642B1 (en) | 2001-12-17 | 2009-05-28 | Egis Gyogyszergyar Nyilvanosan | Amlodipine bezylate tablets having extended stability and process for producing the same |
US20030215526A1 (en) | 2002-03-08 | 2003-11-20 | Scott Stofik | Stable formulations of angiotensin converting enzyme (ACE) inhibitors |
PL1635792T3 (pl) * | 2003-06-26 | 2009-08-31 | Teva Pharmaceutical Industries Ltd | Stabilne kompozycje farmaceutyczne pochodnych kwasu 2-aza-bicyklo[3.3.0]-oktano-3-karboksylowego |
EP1694308A1 (en) | 2003-10-30 | 2006-08-30 | Lupin Ltd. | Stable formulations of ace inhibitors and methods for preparation thereof |
GB2394660A (en) | 2003-12-17 | 2004-05-05 | Niche Generics Ltd | Stabilisation of pharmaceutical compositions comprising ACE inhibitor by absence of acidic excipients having large specific surface area, eg silicon dioxide |
EP1734931A2 (en) | 2004-03-24 | 2006-12-27 | Actavis Group | Formulations of ramipril |
US20060159742A1 (en) * | 2004-11-05 | 2006-07-20 | King Pharmaceutical Research & Development, Inc. | Stabilized individually coated ramipril particles, compositions and methods |
CN100374462C (zh) | 2005-11-21 | 2008-03-12 | 大连帝恩生物工程有限公司 | 截短胰高血糖素样肽1(sGLP-1)、制法及其应用 |
US20070232680A1 (en) * | 2006-04-04 | 2007-10-04 | Vijayabhaskar Bolugoddu | Preparation of ramipril and stable pharmaceutical compositions |
CN101489550A (zh) * | 2006-04-19 | 2009-07-22 | 特瓦制药工业有限公司 | 2-氮杂-二环[3.3.0]-辛烷-3-羧酸衍生物的稳定药物组合物 |
US20080015188A1 (en) * | 2006-04-19 | 2008-01-17 | Julia Hrakovsky | Stable pharmaceutical compositions of 2-aza-bicyclo(3.3.0)-octane-3-carboxylic acid derivatives |
US20070281000A1 (en) * | 2006-06-02 | 2007-12-06 | Michael Fox | Stable formulation comprising moisture sensitive drug/s and manufacturing procedure thereof |
WO2007142628A1 (en) * | 2006-06-02 | 2007-12-13 | Teva Pharmaceutical Industries Ltd. | Stable formulation comprising moisture sensitive drug/s and manufacturing procedure thereof |
US20100035955A1 (en) | 2006-06-30 | 2010-02-11 | Panagiotis Keramidas | Stabilised Composition Comprising ACE Inhibitors |
US20110086092A1 (en) | 2006-08-08 | 2011-04-14 | Accu-Break Technologies, Inc. | Pharmacuetical tablets containing a plurality of active ingredients |
WO2008065485A2 (en) | 2006-10-19 | 2008-06-05 | Torrent Pharmaceuticals Limited | Stable pharmaceutical compositions of a calcium channel blocker and an ace inhibitor |
GB0624087D0 (en) * | 2006-12-01 | 2007-01-10 | Selamine Ltd | Ramipril combination salt |
WO2008068217A2 (en) * | 2006-12-04 | 2008-06-12 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition comprising a coated hmg-coa reductase inhibitor and an inhibitor of the renin-angiotensin system |
PL2120878T3 (pl) | 2007-02-09 | 2015-01-30 | Alphapharm Pty Ltd | Postać dawkowania zawierająca dwa czynne składniki farmaceutyczne o różnych postaciach fizycznych |
WO2008132756A1 (en) | 2007-05-01 | 2008-11-06 | Lupin Limited | Stable pharmaceutical compositions of ramipril |
HU230877B1 (hu) | 2008-09-30 | 2018-11-29 | EGIS Gyógyszergyár NyR | Stabil kombinációs gyógyszerkészítmény |
MA34130B1 (fr) * | 2010-02-24 | 2013-04-03 | Sanofi Aventis Deutschland | Formulations pharmaceutiques solides de ramipril et de bésylate d'amlodipine et leur préparation |
US20150094345A1 (en) | 2012-02-17 | 2015-04-02 | Egis Gyogyszergyar Zrt. | Pharmaceutical formulation having improved stability |
-
2012
- 2012-02-17 US US14/379,382 patent/US20150094345A1/en not_active Abandoned
- 2012-02-17 AU AU2012369903A patent/AU2012369903A1/en not_active Abandoned
- 2012-02-17 EP EP12711438.7A patent/EP2814465B1/en active Active
- 2012-02-17 CN CN201280069949.6A patent/CN104254321A/zh active Pending
- 2012-02-17 HU HUE12711438A patent/HUE046229T2/hu unknown
- 2012-02-17 CN CN201710824593.7A patent/CN107441495A/zh active Pending
- 2012-02-17 UA UAA201410026A patent/UA113977C2/uk unknown
- 2012-02-17 EA EA201491510A patent/EA030466B1/ru not_active IP Right Cessation
- 2012-02-17 PL PL12711438T patent/PL2814465T3/pl unknown
- 2012-02-17 EP EP18209851.7A patent/EP3501501A1/en not_active Withdrawn
- 2012-02-17 MX MX2014009871A patent/MX370647B/es active IP Right Grant
- 2012-02-17 WO PCT/HU2012/000013 patent/WO2013121233A1/en active Application Filing
- 2012-02-17 CA CA2864456A patent/CA2864456A1/en not_active Abandoned
- 2012-02-17 BR BR112014020184-6A patent/BR112014020184B1/pt active IP Right Grant
-
2014
- 2014-08-06 IL IL233972A patent/IL233972A0/en unknown
- 2014-08-13 ZA ZA2014/05925A patent/ZA201405925B/en unknown
- 2014-08-14 PH PH12014501840A patent/PH12014501840A1/en unknown
-
2015
- 2015-06-30 HK HK15106214.0A patent/HK1205683A1/xx unknown
-
2016
- 2016-05-26 AU AU2016203463A patent/AU2016203463A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CN104254321A (zh) | 2014-12-31 |
PL2814465T3 (pl) | 2020-01-31 |
US20150094345A1 (en) | 2015-04-02 |
CA2864456A1 (en) | 2013-08-22 |
CN107441495A (zh) | 2017-12-08 |
IL233972A0 (en) | 2014-09-30 |
EA201491510A1 (ru) | 2014-11-28 |
HK1205683A1 (en) | 2015-12-24 |
EP2814465A1 (en) | 2014-12-24 |
BR112014020184A2 (es) | 2017-06-20 |
EP3501501A1 (en) | 2019-06-26 |
EP2814465B1 (en) | 2019-07-03 |
AU2016203463A1 (en) | 2016-07-07 |
MX2014009871A (es) | 2015-03-19 |
EA030466B1 (ru) | 2018-08-31 |
PH12014501840A1 (en) | 2014-11-10 |
ZA201405925B (en) | 2015-11-25 |
AU2012369903A1 (en) | 2014-09-04 |
BR112014020184A8 (pt) | 2017-07-11 |
BR112014020184B1 (pt) | 2021-11-30 |
UA113977C2 (xx) | 2017-04-10 |
WO2013121233A1 (en) | 2013-08-22 |
HUE046229T2 (hu) | 2020-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TN2014000517A1 (en) | Syringe | |
PH12014000179A1 (en) | New pyrrole compounds, a process for their preparation and pharmaceutical compositions containing them | |
MX2016000264A (es) | Composiciones para curado que contienen grupos sililo y con una estabilidad mejorada de almacenamiento. | |
EP3036231A4 (en) | Substituted pyrimidine compounds, compositions and medicinal applications thereof | |
GB201106750D0 (en) | Novel compounds | |
IN2012DN06714A (es) | ||
EP2968214A4 (en) | Novel analgesic compositions | |
TR201821285T4 (tr) | CCR3 antagonisti içeren farmasötik formülasyonlar. | |
MX364069B (es) | Moduladores de la proteína activadora de 5-lipoxigenasa. | |
BR112014025041B8 (pt) | Composição farmacêutica | |
BR112015002824A2 (pt) | composto, uso de um composto, composição farmacêutica, e, produto farmacêutico de combinação. | |
WO2011084848A3 (en) | Prodrugs of heteraromatic compounds | |
MX2016008369A (es) | Composicion farmaceutica que incluye palonosetron. | |
TR201905787T4 (tr) | Liyofilize TAT-NR2B9C formülasyonu. | |
CA2875305C (en) | Fbxo3 inhibitors | |
AU2018253594A1 (en) | Dihydroxyphenyl neurotransmitter compounds, compositions and methods | |
PH12014501840A1 (en) | Pharmaceutical formulation having improved stability | |
SG11201501122WA (en) | Solid pharmaceutical preparation containing levothyroxine | |
EP3022186A4 (en) | Quinazoline derivatives, compositions thereof, and use as pharmaceuticals | |
MX2015003034A (es) | Jeringa que contiene una composicion, en particular farmaceutica, que comprende inmunoglobulinas, su metodo de fabricacion y uso. | |
PH12015501390A1 (en) | Tablets with improved acceptance and good storage stability | |
EP2784061A4 (en) | ACYLHYDRACO AND OXADIAZOL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE THEREOF | |
MX2015016766A (es) | Nuevos derivados de tetrazolona. | |
MX2014004210A (es) | Derivados de 2-oxo-piperidinilo. | |
HUP1600414A2 (hu) | Bisoprololt és ramiprilt tartalmazó stabil kombinációs gyógyszerkészítmény |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |